QNTM Quantum BioPharma
Price Chart
Executive Summary
Quantum BioPharma has closed the first tranche of its offering, raising $3.75 million through the issuance of 3,750 Debenture Units, with a director participating for $300,000. The company also completed a debt settlement by issuing 370,457 Class B shares to settle $1.12 million in debt, including obligations to insiders. Both transactions are related-party dealings exempt from formal valuation and shareholder approval under MI 61-101.
Key Financial Metrics
Actionable Insight
Monitor for additional tranches of the offering and further debt settlements, which could increase dilution. Assess whether the capital raised meaningfully advances the company's drug development programs, particularly Lucid-MS.
Key Facts
- Quantum BioPharma raised $3,750,000 in the first tranche of its offering through 3,750 Debenture Units.
- A director participated in the offering, subscribing for $300,000 worth of Debenture Units, constituting a related-party transaction.
- The company settled $1,117,727 in debt by issuing 370,457 Class B subordinate voting shares to creditors, including insiders.
- Both the offering and debt settlement are exempt from minority shareholder approval under MI 61-101 due to size relative to market cap.
- Proceeds will be used for business development and general working capital purposes.
Financial Impact
$3.75 million raised in debt financing; $1.12 million in debt eliminated via share issuance
Risk Factors
- Dilution risk from future share issuances in additional tranches or debt settlements.
- Related-party transactions may raise governance concerns among minority shareholders.
- Low market cap ($9M) increases sensitivity to dilution and potential stock volatility.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259989 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
6-K
| $5.11 $4.88 | ▲ +4.50% | ▲ +3.81% | $3.89 (+23.87%) |
|
Jun 2, 2026
7d ago
|
6-K
| $5.11 $4.88 | ▼ −4.50% | ▼ −3.78% | $3.89 (−23.87%) |
|
May 18, 2026
22d ago
|
6-K
| $6.27 $7.00 | ▲ +11.64% | ▲ +12.29% | $3.89 (−37.96%) |
|
Apr 22, 2026
6w ago
|
6-K
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $3.89 (+16.12%) |
|
Apr 22, 2026
6w ago
|
Press Release
| $3.35 $3.21 | ▼ −4.18% | ▼ −3.79% | $3.89 (+16.12%) |
|
Apr 2, 2026
9w ago
|
6-K
| $3.98 $3.58 | ▼ −10.05% | ▼ −10.53% | $3.89 (−2.26%) |
|
Apr 1, 2026
9w ago
|
6-K
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $3.89 (−11.79%) |
|
Apr 1, 2026
9w ago
|
Press Release
| $4.41 $3.98 | ▼ −9.75% | ▼ −9.83% | $3.89 (−11.79%) |
|
Mar 30, 2026
10w ago
|
Court Ruling
| $4.28 $4.83 | ▲ +12.85% | ▲ +9.96% | $3.89 (−9.11%) |
|
Mar 27, 2026
10w ago
|
6-K
| $4.77 $4.28 | ▼ −10.27% | ▼ −9.91% | $3.89 (−18.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access